Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

“nobody calls it TMVI—they call it transcatheter mitral valve replacement. And it’s essentially doing the same thing in that regard.” Francesco Pelliccia, MD (Sapienza University of Rome, Italy), ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

The US Centers for Medicare & Medicaid Services (CMS) has finalized its national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR) when used to treat patients with ...